Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...

When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society is ...

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

The Going the Extra Mile to End the HIV Epidemic Report – launched by Gilead Sciences in collaboration with Boston Consulting Group (BCG) and reviewed by three co-authors: Dr Shannon Hader ...

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...